Briviact, Briviact (in italy: nubriveo)(brivaracetam)
Briviact (brivaracetam) is a small molecule pharmaceutical. Brivaracetam was first approved as Briviact (in italy: nubriveo) on 2016-01-13. It is used to treat seizures in the USA. It has been approved in Europe to treat epilepsy. The pharmaceutical is active against synaptic vesicle glycoprotein 2A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Briviact (discontinued: Brivaracetam)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| briviact | New Drug Application | 2025-09-10 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
BRIVARACETAM, BRIVIACT, UCB INC | |||
| 2024-08-27 | NPP | ||
HCPCS
No data
Clinical
Clinical Trials
57 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 5 | 8 | 21 | — | 6 | 38 |
| Seizures | D012640 | — | G40.4 | 1 | 5 | 9 | — | 1 | 16 |
| Absence epilepsy | D004832 | — | G40.A | — | — | 3 | — | — | 3 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | 2 | — | — | 2 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | 1 | 1 | — | — | 2 |
| Unverricht-lundborg syndrome | D020194 | Orphanet_308 | G40.3 | — | — | 2 | — | — | 2 |
| Neuralgia | D009437 | EFO_0009430 | — | — | 1 | 1 | — | — | 2 |
| Reflex epilepsy | D020195 | EFO_1001146 | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Partial epilepsies | D004828 | EFO_0004263 | — | — | 1 | — | — | 2 | 3 |
| Postherpetic neuralgia | D051474 | — | — | — | 1 | — | — | — | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | 1 | — | — | — | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 6 | — | — | — | — | 6 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast feeding | D001942 | — | — | — | — | — | — | 1 | 1 |
| Status epilepticus | D013226 | EFO_0008526 | G41 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Brivaracetam |
| INN | brivaracetam |
| Description | Brivaracetam is a non-proteinogenic amino acid derivative that is butanamide in which the pro-S hydrogen at position 2 is replaced by a (4R)-2-oxo-4-propylpyrrolidin-1-yl. Used for treatment of partial onset seizures related to epilepsy. It has a role as an anticonvulsant. It is a gamma-lactam and a non-proteinogenic amino acid derivative. It is functionally related to a L-alpha-aminobutyric acid. |
| Classification | Small molecule |
| Drug class | nootropic agents (learning, cognitive enhancers), piracetam type |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC[C@@H]1CC(=O)N([C@@H](CC)C(N)=O)C1 |
Identifiers
| PDB | — |
| CAS-ID | 357336-20-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL607400 |
| ChEBI ID | — |
| PubChem CID | 9837243 |
| DrugBank | DB05541 |
| UNII ID | U863JGG2IA (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,513 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,584 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use